Pharmacological inhibition of MerTK or AXL, when combined with radiotherapy or chemotherapy, augments the immunogenicity of tumor cell death, increases antigen release, and thereby strengthens adaptive immune activation [201]. This evidence concerns the gene MERTK and neoplasm.